Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer

Japan Clinical Oncology Group study, JCOG 9208

Yutaka Tokuda, Tomoo Tajima, Masaru Narabayashi, Kunihiko Takeyama, Toru Watanabe, Takashi Fukutomi, Takaaki Chou, Muneaki Sano, Tadahiko Igarashi, Yasutsuna Sasaki, Michinori Ogura, Shigeto Miura, Shinichiro Okamoto, Masami Ogita, Masaharu Kasai, Tadashi Kobayashi, Haruhiko Fukuda, Shigemitsu Takashima, Kensei Tobinai

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A randomized controlled trial was conducted to evaluate the efficacy of high-dose chemotherapy (HDC) as consolidation of the treatment of high-risk postoperative breast cancer. Patients under 56 years of age with stage I to IIIB breast cancer involving 10 or more axillary lymph nodes were eligible. The primary endpoint was relapse-free survival (RFS). Between May 1993 and March 1999, 97 patients were enrolled, and two patients became ineligible. The median age of the 97 patients was 46 years (range 27-55 years), and 72 (74%) were premenopausal. The median number of involved axillary nodes was 16 (range 10-49). All patients had undergone a radical mastectomy. Major characteristics were well balanced between the treatment arms. Forty-eight patients in the standard-dose (STD) arm received six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen. Forty-nine patients were assigned to undergo HDC with cyclophosphamide and thiotepa after six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen; however, 15 of these patients (31%) did not undergo HDC. HDC was well tolerated without any treatment-related mortality. At a median follow-up of 63 months, the 5-year RFS of 47 eligible patients in the STD arm and 48 eligible patients in the HDC arm was 37% and 52% on an intent-to-treat basis, respectively (P = 0.17). Five-year overall survival of all randomized patients was 62% for the STD arm and 63% for the HDC arm (P = 0.78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalCancer Science
Volume99
Issue number1
DOIs
Publication statusPublished - 2008 Jan

Fingerprint

Consolidation Chemotherapy
Medical Oncology
Japan
Breast Neoplasms
Drug Therapy
Survival
Therapeutics
Cyclophosphamide
Tamoxifen
Recurrence
Fluorouracil
Doxorubicin
Thiotepa
Radical Mastectomy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer : Japan Clinical Oncology Group study, JCOG 9208. / Tokuda, Yutaka; Tajima, Tomoo; Narabayashi, Masaru; Takeyama, Kunihiko; Watanabe, Toru; Fukutomi, Takashi; Chou, Takaaki; Sano, Muneaki; Igarashi, Tadahiko; Sasaki, Yasutsuna; Ogura, Michinori; Miura, Shigeto; Okamoto, Shinichiro; Ogita, Masami; Kasai, Masaharu; Kobayashi, Tadashi; Fukuda, Haruhiko; Takashima, Shigemitsu; Tobinai, Kensei.

In: Cancer Science, Vol. 99, No. 1, 01.2008, p. 145-151.

Research output: Contribution to journalArticle

Tokuda, Y, Tajima, T, Narabayashi, M, Takeyama, K, Watanabe, T, Fukutomi, T, Chou, T, Sano, M, Igarashi, T, Sasaki, Y, Ogura, M, Miura, S, Okamoto, S, Ogita, M, Kasai, M, Kobayashi, T, Fukuda, H, Takashima, S & Tobinai, K 2008, 'Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208', Cancer Science, vol. 99, no. 1, pp. 145-151. https://doi.org/10.1111/j.1349-7006.2007.00639.x
Tokuda, Yutaka ; Tajima, Tomoo ; Narabayashi, Masaru ; Takeyama, Kunihiko ; Watanabe, Toru ; Fukutomi, Takashi ; Chou, Takaaki ; Sano, Muneaki ; Igarashi, Tadahiko ; Sasaki, Yasutsuna ; Ogura, Michinori ; Miura, Shigeto ; Okamoto, Shinichiro ; Ogita, Masami ; Kasai, Masaharu ; Kobayashi, Tadashi ; Fukuda, Haruhiko ; Takashima, Shigemitsu ; Tobinai, Kensei. / Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer : Japan Clinical Oncology Group study, JCOG 9208. In: Cancer Science. 2008 ; Vol. 99, No. 1. pp. 145-151.
@article{15d0eb75645345dfb92f37a3eec0f35c,
title = "Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208",
abstract = "A randomized controlled trial was conducted to evaluate the efficacy of high-dose chemotherapy (HDC) as consolidation of the treatment of high-risk postoperative breast cancer. Patients under 56 years of age with stage I to IIIB breast cancer involving 10 or more axillary lymph nodes were eligible. The primary endpoint was relapse-free survival (RFS). Between May 1993 and March 1999, 97 patients were enrolled, and two patients became ineligible. The median age of the 97 patients was 46 years (range 27-55 years), and 72 (74{\%}) were premenopausal. The median number of involved axillary nodes was 16 (range 10-49). All patients had undergone a radical mastectomy. Major characteristics were well balanced between the treatment arms. Forty-eight patients in the standard-dose (STD) arm received six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen. Forty-nine patients were assigned to undergo HDC with cyclophosphamide and thiotepa after six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen; however, 15 of these patients (31{\%}) did not undergo HDC. HDC was well tolerated without any treatment-related mortality. At a median follow-up of 63 months, the 5-year RFS of 47 eligible patients in the STD arm and 48 eligible patients in the HDC arm was 37{\%} and 52{\%} on an intent-to-treat basis, respectively (P = 0.17). Five-year overall survival of all randomized patients was 62{\%} for the STD arm and 63{\%} for the HDC arm (P = 0.78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival.",
author = "Yutaka Tokuda and Tomoo Tajima and Masaru Narabayashi and Kunihiko Takeyama and Toru Watanabe and Takashi Fukutomi and Takaaki Chou and Muneaki Sano and Tadahiko Igarashi and Yasutsuna Sasaki and Michinori Ogura and Shigeto Miura and Shinichiro Okamoto and Masami Ogita and Masaharu Kasai and Tadashi Kobayashi and Haruhiko Fukuda and Shigemitsu Takashima and Kensei Tobinai",
year = "2008",
month = "1",
doi = "10.1111/j.1349-7006.2007.00639.x",
language = "English",
volume = "99",
pages = "145--151",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer

T2 - Japan Clinical Oncology Group study, JCOG 9208

AU - Tokuda, Yutaka

AU - Tajima, Tomoo

AU - Narabayashi, Masaru

AU - Takeyama, Kunihiko

AU - Watanabe, Toru

AU - Fukutomi, Takashi

AU - Chou, Takaaki

AU - Sano, Muneaki

AU - Igarashi, Tadahiko

AU - Sasaki, Yasutsuna

AU - Ogura, Michinori

AU - Miura, Shigeto

AU - Okamoto, Shinichiro

AU - Ogita, Masami

AU - Kasai, Masaharu

AU - Kobayashi, Tadashi

AU - Fukuda, Haruhiko

AU - Takashima, Shigemitsu

AU - Tobinai, Kensei

PY - 2008/1

Y1 - 2008/1

N2 - A randomized controlled trial was conducted to evaluate the efficacy of high-dose chemotherapy (HDC) as consolidation of the treatment of high-risk postoperative breast cancer. Patients under 56 years of age with stage I to IIIB breast cancer involving 10 or more axillary lymph nodes were eligible. The primary endpoint was relapse-free survival (RFS). Between May 1993 and March 1999, 97 patients were enrolled, and two patients became ineligible. The median age of the 97 patients was 46 years (range 27-55 years), and 72 (74%) were premenopausal. The median number of involved axillary nodes was 16 (range 10-49). All patients had undergone a radical mastectomy. Major characteristics were well balanced between the treatment arms. Forty-eight patients in the standard-dose (STD) arm received six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen. Forty-nine patients were assigned to undergo HDC with cyclophosphamide and thiotepa after six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen; however, 15 of these patients (31%) did not undergo HDC. HDC was well tolerated without any treatment-related mortality. At a median follow-up of 63 months, the 5-year RFS of 47 eligible patients in the STD arm and 48 eligible patients in the HDC arm was 37% and 52% on an intent-to-treat basis, respectively (P = 0.17). Five-year overall survival of all randomized patients was 62% for the STD arm and 63% for the HDC arm (P = 0.78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival.

AB - A randomized controlled trial was conducted to evaluate the efficacy of high-dose chemotherapy (HDC) as consolidation of the treatment of high-risk postoperative breast cancer. Patients under 56 years of age with stage I to IIIB breast cancer involving 10 or more axillary lymph nodes were eligible. The primary endpoint was relapse-free survival (RFS). Between May 1993 and March 1999, 97 patients were enrolled, and two patients became ineligible. The median age of the 97 patients was 46 years (range 27-55 years), and 72 (74%) were premenopausal. The median number of involved axillary nodes was 16 (range 10-49). All patients had undergone a radical mastectomy. Major characteristics were well balanced between the treatment arms. Forty-eight patients in the standard-dose (STD) arm received six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen. Forty-nine patients were assigned to undergo HDC with cyclophosphamide and thiotepa after six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen; however, 15 of these patients (31%) did not undergo HDC. HDC was well tolerated without any treatment-related mortality. At a median follow-up of 63 months, the 5-year RFS of 47 eligible patients in the STD arm and 48 eligible patients in the HDC arm was 37% and 52% on an intent-to-treat basis, respectively (P = 0.17). Five-year overall survival of all randomized patients was 62% for the STD arm and 63% for the HDC arm (P = 0.78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival.

UR - http://www.scopus.com/inward/record.url?scp=36949036941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36949036941&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00639.x

DO - 10.1111/j.1349-7006.2007.00639.x

M3 - Article

VL - 99

SP - 145

EP - 151

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -